Pfizer Inc. and German partner BioNTech SE said Tuesday they have submitted initial data from the late-stage trial of their COVID-19 vaccine in children aged 5 to 12 to the U.S. Food and Drug Administration, and are seeking an Emergency Use Authorization to add that patient group to the program. The news comes after the companies released initial data from the trial last week, saying the vaccine had proved safe and effective. The companies used two doses of just 10 mg in a trial involving 2,268 participants. “Topline immunogenicity and safety readouts for the other two age cohorts from the trial — children 2 to Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
- Crypto: An Ether futures ETF is next likely step after ProShares watershed bitcoin moment, a former SEC official explains - October 24, 2021
- Mutual Funds Weekly: These money and investing tips can help you hit whatever pitch the market delivers - October 24, 2021
- NewsWatch: Big Tech stocks are the market’s superstars but rising rates could bring them down - October 23, 2021